Compass Therapeutics, Inc. (CMPX) Form 8-K — May 5, 2026
Compass Therapeutics reported a first quarter 2026 net loss of $18.3 million, or $0.10 per share, compared to a net loss of $16.6 million, or $0.12 per share, in the prior year period. The company ended the quarter with $195 million in cash and marketable securities, which management expects will fund operations into 2028. The company highlighted positive Phase 2/3 data for its lead candidate tovecimig in biliary tract cancer, demonstrating a statistically significant improvement in progression-free survival and an overall response rate of 17.1% versus 5.3% for the control arm.
Key figures
- Eps
- -$0.10
- Net Income
- -$18.3 million
- Cash Position
- $195 million
- Runway
- into 2028
- G&A expenses
- $6.9 million
- R&D expenses
- $13.4 million
- ORR tovecimig
- 17.1%
- PFS tovecimig
- 4.7 months
Price after filing
Close on the filing date to close N calendar days later (from $1.95). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.